Monday 16 November 2026
Export BRVE’s income statement to Excel — free account
Braveheart Bio, Inc.
BRVE- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
19.62
0.88
−4.29%
Follow BRVE
Alert me
Ratios over time Q4 FY25 to Q3 FY26
Returns on capital
ROIC was -28.7% in Q3 FY26, the lowest of these four quarters. ROE, at 0.0%, is far above it because equity is small against the capital the business uses.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| ROE | 0.0% | 0.0% | 0.0% | 0.0% |
| ROIC | 0.0% | 0.0% | 0.0% | −28.7% |
Debt
Net debt is 11.58× a year’s EBITDA.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Net debt / EBITDA | 12.8× | 5.3× | 7.7× | 11.6× |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Current Ratio |
+3 more quarters Free account |
17.03 | 8.11 | 13.63 | 21.57 |
Net Debt/EBITDA |
12.77 | 5.34 | 7.72 | 11.58 | |
Debt/Assets |
0.00% | 0.36% | 0.16% | 0.02% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.20 | 0.36 | 0.91 | 0.92 | |
Capex/Depreciation |
— | (18.00) | 2.67 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.33) | (0.76) | (2.29) | (0.47) | |
Cash per Share |
23.22 | 11.74 | 16.59 | 6.70 | |
Shareholders Equity per Share |
(17.15) | (11.42) | (12.96) | 9.55 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(17.15) | (11.42) | (12.96) | 9.55 | |
Free Cash Flow |
(1.27) | (5.22) | (16.94) | (24.37) | |
Working Capital |
84.04 | 71.07 | 114.39 | 342.90 | |
Capital Expenditures |
— | (0.04) | 0.01 | 0.00 | |
Net Current Asset Value |
(65.94) | (79.20) | (99.42) | 342.73 | |
| Other line items | |||||
Quick Ratio |
17.01 | 8.06 | 13.56 | 20.95 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.33) | (0.76) | (2.29) | (0.47) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 12 Nov 2026